Cipla strikes Serum deal to break into vaccines; Amgen opens biologics plant in Singapore;

@FiercePharma: ICYMI: This week's full issue of FiercePharmaMarketing. Subscribe here. | Follow @FiercePharma

@CarlyHFierce: U.K. health secretary: Novartis holding government to 'ransom' with Bexsero pricing. FierceVaccines article | Follow @CarlyHFierce

> India's Cipla has entered the vaccines space with a deal with the Serum Institute of India, whose low-cost pediatric vaccines it will market in Europe. More

> Amgen ($AMGN) has opened a $200 million continuous purification plant in Singapore. More

> Perrigo says it plans to sell $900 million in stock to fund its acquisition of Belgium's Omega Pharma. Report (sub. req.)

> Multinational pharmas are selling their drugs at higher prices in South Korea than in other countries, a report says. More

> AstraZeneca ($AZN) has priced a new debt issue of 750 million in euro-denominated notes. Report

Medical Device News

@FierceMedDev: From FierceDrugDelivery: Medical marijuana company licenses RapidMist device for buccal delivery. Story | Follow @FierceMedDev

@StacyALawrence: Second Sight IPO pops 122% in first day. That's 8th largest IPO pop this year in any sector. Updated story | Follow @StacyALawrence

@VarunSaxena2: Smith & Nephew closes U.S. facility, sells another in U.K. with 100+ to be laid off. More | Follow @VarunSaxena2

@EmilyWFierce: More on how the Cystic Fibrosis Foundation's deal with Royalty Pharma could affect R&D and patients. NYT story | Follow @EmilyWFierce

> Smith & Nephew closes a facility in the U.S., sells another in the UK, 100+ to be laid off. More

> New paradigms in diagnostics: graphene and a single drop of blood. Editor's Corner

> Molecular nuclear imaging startup to use $100M IPO to advance Phase III therapeutic. Article

Biotech News

@FierceBiotech: Success or failure, feds want trial results posted online. Article | Follow @FierceBiotech

@JohnCFierce: U.K. heavyweight Woodford gambles $25M on controversial brain cancer vaccine. Report | Follow @JohnCFierce

@DamianFierce: Important M&A code name update from @BloombergNews: $AGN was "Avocado" to $ACT and "Apollo" to $VRX. Article | Follow @DamianFierce

> U.K. heavyweight Woodford gambles $25M on controversial brain cancer vaccine. Article

> Success or failure, feds want trial results posted online. More

> Sanofi sticks to Viehbacher's R&D script as it rolls out a $38B pipeline vision. Story

Vaccines News

> PATH chooses Mymetics for work on transmission-blocking malaria vax. Item

> U.K. health secretary: Novartis holding government to 'ransom' with Bexsero pricing. More

> Pfizer's MenB reach--and lead on Novartis--limited without ACIP nod. Report

> NewLink Ebola vaccine trial to start in Canada. Article

> Celldex glioblastoma vaccine extends survival in Phase II. Story

Pharma Manufacturing News

> Ranbaxy can't stop the FDA from yanking drug approvals over plant problems. Item

> Amgen opens $200M continuous purification plant in Singapore. Story

> Doc coughs up $2M for using unapproved Avastin on his cancer patients. Report

> Interpol: Organized crime, aware of weak points, targets counterfeit drugs. Story

> U.K. generics maker to build $31M plant in Alabama. Article

And Finally... The British government has launched a review to speed the path to market for new drugs. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.